CY1117437T1 - Αντισωματα αντι-μεσοθηλινης και χρησεις αυτων - Google Patents

Αντισωματα αντι-μεσοθηλινης και χρησεις αυτων

Info

Publication number
CY1117437T1
CY1117437T1 CY20161100353T CY161100353T CY1117437T1 CY 1117437 T1 CY1117437 T1 CY 1117437T1 CY 20161100353 T CY20161100353 T CY 20161100353T CY 161100353 T CY161100353 T CY 161100353T CY 1117437 T1 CY1117437 T1 CY 1117437T1
Authority
CY
Cyprus
Prior art keywords
antibodies
tumors
binding domains
mesothelin
antigen
Prior art date
Application number
CY20161100353T
Other languages
English (en)
Inventor
Antje Kahnert
David Light
Doug Schneider
Renate Parry
Noboru Satozawa
Hansen Tara Renee Heitner
Stefan Steidl
Ulrike Schubert
Original Assignee
Bayer Intellectual Property Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Intellectual Property Gmbh filed Critical Bayer Intellectual Property Gmbh
Publication of CY1117437T1 publication Critical patent/CY1117437T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει ανασυνδυασμένες περιοχές πρόσδεσης αντιγόνου και αντισώματα και λειτουργικά τμήματα που περιέχουν τέτοιες περιοχές πρόσδεσης αντιγόνου που είναι ειδικές για το αγκυροβολημένο στην μεμβράνη, 4O kDa πεπτίδιο της μεσοθηλίνης, το οποίο υπερεκφράζεται σε πολλούς όγκους, όπως παγκρεατικούς και όγκους ωοθηκών, στο μεσοθηλίωμα και σε κύτταρα καρκίνου του πνεύμονα. Αυτά τα αντισώματα, συνεπώς, μπορεί να χρησιμοποιηθούν για να θεραπεύσουν αυτές και άλλες διαταραχές και καταστάσεις. Αντισώματα της εφεύρεσης μπορούν επίσης να χρησιμοποιηθούν στον διαγνωστικό τομέα, καθώς και για περαιτέρω έρευνα του ρόλου της μεσοθηλίνης στην εξέλιξη διαταραχών που σχετίζονται με καρκίνο. Η εφεύρεση παρέχει επίσης αλληλουχίες νουκλεϊκών οξέων που κωδικοποιούν τα προαναφερθέντα αντισώματα, φορείς που περιλαμβάνουν τις ίδιες, φαρμακευτικές συνθέσεις και κιτ με οδηγίες για χρήση.
CY20161100353T 2007-11-26 2016-04-27 Αντισωματα αντι-μεσοθηλινης και χρησεις αυτων CY1117437T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US437807P 2007-11-26 2007-11-26
EP08855189.0A EP2215121B1 (en) 2007-11-26 2008-11-19 Anti-mesothelin antibodies and uses therefor

Publications (1)

Publication Number Publication Date
CY1117437T1 true CY1117437T1 (el) 2017-04-26

Family

ID=40351874

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100353T CY1117437T1 (el) 2007-11-26 2016-04-27 Αντισωματα αντι-μεσοθηλινης και χρησεις αυτων

Country Status (31)

Country Link
US (3) US9023351B2 (el)
EP (3) EP3103814A1 (el)
JP (3) JP5608091B2 (el)
KR (1) KR101559599B1 (el)
CN (2) CN104151429B (el)
AU (1) AU2008329221B2 (el)
BR (1) BRPI0819909B8 (el)
CA (1) CA2706529C (el)
CO (1) CO6280409A2 (el)
CR (1) CR11456A (el)
CU (1) CU23833A3 (el)
CY (1) CY1117437T1 (el)
DK (1) DK2215121T3 (el)
DO (1) DOP2010000150A (el)
EC (1) ECSP10010191A (el)
ES (1) ES2569513T3 (el)
GT (1) GT201000148A (el)
HK (2) HK1148541A1 (el)
HN (1) HN2010001062A (el)
HR (1) HRP20160485T1 (el)
HU (1) HUE027358T2 (el)
IL (1) IL205681A0 (el)
MA (1) MA31862B1 (el)
MX (1) MX2010005603A (el)
MY (1) MY157164A (el)
NZ (1) NZ585551A (el)
PL (1) PL2215121T3 (el)
SI (1) SI2215121T1 (el)
TN (1) TN2010000234A1 (el)
UA (1) UA106036C2 (el)
WO (1) WO2009068204A1 (el)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2195017T3 (pl) * 2007-10-01 2015-03-31 Bristol Myers Squibb Co Ludzkie antyciała, które wiążą mezotelinę i ich zastosowania
US9023351B2 (en) * 2007-11-26 2015-05-05 Bayer Intellectual Property Gmbh Anti-mesothelin antibodies and uses thereof
UY32560A (es) * 2009-04-29 2010-11-30 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
AU2011349443B2 (en) * 2010-12-20 2015-12-24 Genentech, Inc. Anti-mesothelin antibodies and immunoconjugates
EP3138581B1 (en) 2011-03-17 2019-01-02 The University of Birmingham Re-directed immunotherapy
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
EP2699268A2 (de) 2011-04-21 2014-02-26 Seattle Genetics, Inc. Neue binder-wirkstoff konjugate (adcs) und ihre verwendung
WO2014004549A2 (en) * 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
CA2885761C (en) * 2012-09-27 2021-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin antibodies and methods for eliciting potent antitumor activity
CN103819559B (zh) * 2013-12-10 2016-02-24 中国科学院武汉病毒研究所 一种抗间皮素纳米抗体及其编码基因和该纳米抗体的用途
NZ720736A (en) 2013-12-23 2020-08-28 Bayer Pharma AG Antibody drug conjugates (adcs) with kinesin spindel protein (ksp)
WO2016050822A2 (en) 2014-09-30 2016-04-07 Neurimmune Holding Ag Human-derived anti-dipeptide repeats (dprs) antibody
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
EP3466967A1 (en) 2015-05-18 2019-04-10 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
CN108025084A (zh) 2015-06-22 2018-05-11 拜耳医药股份有限公司 具有酶可裂解基团的抗体药物缀合物（adc）和抗体前药缀合物（apdc）
TW201718641A (zh) * 2015-06-30 2017-06-01 偉東 姜 抗血管內皮生長因子受體２（ｖｅｇｆｒ２）抗體
CA2996060A1 (en) * 2015-08-21 2017-03-02 Carsgen Therapeutics, Ltd Fully human anti-mesothelin antibodies and immune effector cells targeting mesothelin
KR101782487B1 (ko) * 2015-09-24 2017-09-27 재단법인 목암생명과학연구소 신규 항-메소텔린 항체 및 이를 포함하는 조성물
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
CN109069597A (zh) 2015-12-22 2018-12-21 诺华股份有限公司 间皮素嵌合抗原受体(car)和抗pd-l1抗体抑制剂联用于抗癌治疗
ES2944597T3 (es) 2015-12-30 2023-06-22 Novartis Ag Terapias con células efectoras inmunitarias de eficacia mejorada
WO2017141604A1 (ja) * 2016-02-15 2017-08-24 地方独立行政法人神奈川県立病院機構 膜型ムチン様タンパク質の認識とその医療応用
WO2017149515A1 (en) 2016-03-04 2017-09-08 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
US11549099B2 (en) 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
WO2017162663A1 (de) 2016-03-24 2017-09-28 Bayer Pharma Aktiengesellschaft Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen
SG11201809041TA (en) 2016-04-15 2018-11-29 Novartis Ag Compositions and methods for selective protein expression
PE20190562A1 (es) 2016-05-27 2019-04-22 Abbvie Biotherapeutics Inc Proteinas de union biespecificas que se unen a una proteina inmunomoduladora y un antigeno tumoral
JP7022707B2 (ja) 2016-06-15 2022-02-18 バイエル・ファルマ・アクティエンゲゼルシャフト Ｋｓｐ阻害剤および抗ｃｄ１２３抗体を含む特異的抗体－薬物－コンジュゲート（ａｄｃ）
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
EP3490590A2 (en) 2016-08-01 2019-06-05 Novartis AG Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
CN109715668A (zh) 2016-08-02 2019-05-03 T细胞受体治疗公司 用于使用融合蛋白进行tcr重编程的组合物和方法
WO2018048975A1 (en) 2016-09-09 2018-03-15 Bristol-Myers Squibb Company Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment
PT3445787T (pt) 2016-10-07 2021-03-15 Tcr2 Therapeutics Inc Composições e métodos para reprogramação de recetores de célula t com o uso de proteínas de fusão
CN110177803A (zh) 2016-11-22 2019-08-27 T细胞受体治疗公司 用于使用融合蛋白进行tcr重新编程的组合物和方法
CA3045466A1 (en) 2016-12-01 2018-06-07 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
CN110072556B (zh) 2016-12-21 2023-05-02 拜耳制药股份公司 具有ksp抑制剂的特异性抗体药物缀合物(adc)
WO2018114798A1 (de) 2016-12-21 2018-06-28 Bayer Aktiengesellschaft Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen
KR102583006B1 (ko) 2016-12-21 2023-09-27 바이엘 파마 악티엔게젤샤프트 효소적으로 절단가능한 기를 갖는 항체 약물 접합체 (adc)
US11535662B2 (en) 2017-01-26 2022-12-27 Novartis Ag CD28 compositions and methods for chimeric antigen receptor therapy
WO2018232020A1 (en) 2017-06-13 2018-12-20 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
JP6339283B1 (ja) 2017-10-31 2018-06-06 国立大学法人 岡山大学 Ｄｎａ、ポリペプチド、抗メソセリン抗体、腫瘍イメージング剤及び複合体
WO2019105835A1 (en) 2017-11-29 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib and anetumab ravtansine
TW201930355A (zh) 2017-12-19 2019-08-01 英商Ｆ星貝塔有限公司 結合物件(三)
WO2019124468A1 (ja) 2017-12-24 2019-06-27 ノイルイミューン・バイオテック株式会社 ヒトメソセリンを特異的に認識する細胞表面分子、ｉｌ－７、及びｃｃｌ１９を発現する免疫担当細胞
US20210047405A1 (en) 2018-04-27 2021-02-18 Novartis Ag Car t cell therapies with enhanced efficacy
WO2019213282A1 (en) 2018-05-01 2019-11-07 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
EP3801769A1 (en) 2018-05-25 2021-04-14 Novartis AG Combination therapy with chimeric antigen receptor (car) therapies
EP3802825A1 (en) 2018-06-08 2021-04-14 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
AU2019327569A1 (en) 2018-08-30 2021-04-29 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
KR20210105890A (ko) 2018-12-17 2021-08-27 레비토프 리미티드 트윈 면역 세포 인게이저
AU2019402189B2 (en) 2018-12-20 2023-04-13 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
BR112021015672A2 (pt) 2019-02-15 2021-10-05 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos
BR112021015783A2 (pt) 2019-02-15 2021-10-05 Novartis Ag Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina-2,6-diona e usos dos mesmos
BR112021017860A2 (pt) * 2019-03-14 2021-12-07 Morphosys Ag Anticorpo ou fragmento de anticorpo isolado específico para c5ar de humano, composição de ácido nucleico, composição de vetor, célula hospedeira e composição farmacêutica
JP2022528020A (ja) 2019-03-19 2022-06-07 フンダシオ プリバダ インスティトゥト ディンベスティガシオ オンコロジカ デ バル エブロン 癌の治療のための併用療法
WO2020234114A1 (en) 2019-05-21 2020-11-26 Bayer Aktiengesellschaft A novel stable high concentration formulation for anetumab ravtansine
WO2021021825A1 (en) * 2019-07-29 2021-02-04 Fred Hutchinson Cancer Research Center Methods and compositions for inducing notch signaling in tumor microenvironments
KR20220116257A (ko) 2019-12-20 2022-08-22 노파르티스 아게 골수섬유증 및 골수이형성 증후군을 치료하기 위한, 데시타빈 또는 항 pd-1 항체 스파르탈리주맙을 포함하거나 또는 포함하지 않는, 항 tim-3 항체 mbg453 및 항 tgf-베타 항체 nis793의 조합물
MX2022007688A (es) 2019-12-20 2022-07-19 Amgen Inc Constructos de anticuerpo multiespecificos agonistas de cd40 dirigidos a mesotelina para el tratamiento de tumores solidos.
CA3185455A1 (en) 2020-06-11 2021-12-16 Novartis Ag Zbtb32 inhibitors and uses thereof
CN115916199A (zh) 2020-06-23 2023-04-04 诺华股份有限公司 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
JP2023536164A (ja) 2020-08-03 2023-08-23 ノバルティス アーゲー ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
TW202321296A (zh) 2021-10-06 2023-06-01 美商鏈接免疫療法公司 抗間皮素抗原結合分子及其用途
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2024050524A1 (en) 2022-09-01 2024-03-07 University Of Georgia Research Foundation, Inc. Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death
WO2024089013A1 (en) 2022-10-25 2024-05-02 Peptomyc, S.L. Combination therapy for the treatment of cancer
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)
CN117843793A (zh) * 2024-03-07 2024-04-09 深圳真实生物医药科技有限公司 抗间皮素抗体、抗原结合片段及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
ES2176484T3 (es) * 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
EP0871492B1 (en) * 1996-01-05 2003-11-26 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services Mesothelium antigen and methods and kits for targeting it
DE69833459T2 (de) 1997-12-01 2006-08-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antikörper, sowie fv moleküle, und immunkonjugate mit hoher bindungsaffinität für mesothelin und methoden für deren verwendung
US6809184B1 (en) 1997-12-01 2004-10-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use
CA2369433A1 (en) * 1999-02-26 2000-08-31 Pacific Northwest Research Institute Methods and compositions for diagnosing carcinomas
IL142025A0 (en) 1999-07-20 2002-03-10 Morphosys Ag Novel methods for displaying (poly) peptides/proteins on bacteriophage particles via disulfide bonds
WO2006099141A2 (en) 2005-03-10 2006-09-21 Morphotek, Inc. Anti-mesothelin antibodies
US20090047211A1 (en) * 2005-05-12 2009-02-19 The Govt. Of The U.S. As Represented By The Sec. Of The Dept. Of Health And Human Services Anti-mesothelin antibodies useful for immunological assays
PT3620171T (pt) 2005-05-18 2022-06-30 Morphosys Ag Anticorpos anti-gm-csf e suas utilizações
AU2006252733A1 (en) 2005-06-02 2006-12-07 Astrazeneca Ab Antibodies directed to CD20 and uses thereof
PL2195017T3 (pl) * 2007-10-01 2015-03-31 Bristol Myers Squibb Co Ludzkie antyciała, które wiążą mezotelinę i ich zastosowania
US9023351B2 (en) * 2007-11-26 2015-05-05 Bayer Intellectual Property Gmbh Anti-mesothelin antibodies and uses thereof

Also Published As

Publication number Publication date
HK1148541A1 (en) 2011-09-09
NZ585551A (en) 2012-06-29
HRP20160485T1 (hr) 2016-06-03
CR11456A (es) 2010-11-12
US20180258181A1 (en) 2018-09-13
UA106036C2 (uk) 2014-07-25
US20150259433A1 (en) 2015-09-17
KR101559599B1 (ko) 2015-10-12
HN2010001062A (es) 2013-10-07
TN2010000234A1 (en) 2011-11-11
CN104151429B (zh) 2018-07-10
DK2215121T3 (en) 2016-05-02
CN101952319A (zh) 2011-01-19
SI2215121T1 (sl) 2016-06-30
CN104151429A (zh) 2014-11-19
ECSP10010191A (es) 2010-07-30
IL205681A0 (en) 2010-11-30
CA2706529C (en) 2016-10-25
AU2008329221B2 (en) 2013-11-07
US9023351B2 (en) 2015-05-05
AU2008329221A1 (en) 2009-06-04
WO2009068204A1 (en) 2009-06-04
CA2706529A1 (en) 2009-06-04
KR20100097660A (ko) 2010-09-03
MA31862B1 (fr) 2010-11-01
GT201000148A (es) 2014-04-03
MX2010005603A (es) 2010-08-02
JP2014221064A (ja) 2014-11-27
HK1200856A1 (en) 2015-08-14
JP2011504372A (ja) 2011-02-10
EP3103814A1 (en) 2016-12-14
BRPI0819909A2 (pt) 2017-12-19
MY157164A (en) 2016-05-13
PL2215121T3 (pl) 2016-07-29
BRPI0819909B8 (pt) 2021-05-25
ES2569513T3 (es) 2016-05-11
JP5608091B2 (ja) 2014-10-15
JP2018102311A (ja) 2018-07-05
CU23833A3 (es) 2012-10-15
HUE027358T2 (en) 2016-09-28
JP6717869B2 (ja) 2020-07-08
CN101952319B (zh) 2015-04-15
EP2215121A1 (en) 2010-08-11
DOP2010000150A (es) 2010-09-15
EP2215121B1 (en) 2016-02-10
US20110027268A1 (en) 2011-02-03
EP2634196A1 (en) 2013-09-04
CO6280409A2 (es) 2011-05-20
BRPI0819909B1 (pt) 2021-04-20

Similar Documents

Publication Publication Date Title
CY1117437T1 (el) Αντισωματα αντι-μεσοθηλινης και χρησεις αυτων
CY1119051T1 (el) Αντισωματα anti-c4.4a και χρησεις αυτων
CY1122627T1 (el) Αντισωματα εναντι της ceacam6 και χρησεις αυτων
CY1119738T1 (el) Ανοσοσυζευγματα αντι-μεσοθηλινης και χρησεις αυτων
CY1116458T1 (el) Ανθρωπινα αντισωματα anti-cd38 και οι χρησεις εξ' αυτων
EA201892616A1 (ru) Антитела к pd1 и lag3 для лечения злокачественного новообразования
CY1117236T1 (el) Μονοκλωνικα αντισωματα εναντι γλυπικανης-3
CY1119539T1 (el) Πληρως ανθρωπινα αντισωματα ειδικα για to cadμ1
CY1116036T1 (el) Ανθρωπινα αντισωματα τα οποια δεσμευουν μεσοθηλινη, και χρησεις αυτων
BR112022014667A2 (pt) Anticorpos de domínio único de cd28 e construtos multivalentes e multiespecíficos dos mesmos
EA202092735A1 (ru) Антагонизирующее cd73 антитело
CY1118949T1 (el) Ανθρωπινα αντισωματα που προσδενουν cxcr4 και χρησεις αυτων
CY1113089T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα σε ειδικο προστατικο μεμβρανικο αντιγονο (psma)
EA202090227A1 (ru) Анти-lag-3 антитело, обладающее повышенной стабильностью
EA200870021A1 (ru) Человеческие моноклональные антитела к фукозил-gm1 и способы применения анти-фукозил-gm1 антител
EA200870020A1 (ru) Человеческие моноклональные антитела против о8е
EA201890169A1 (ru) Тау-связывающие антитела
EA201890796A1 (ru) Новое антитело к мезотелину и содержащая его композиция
EA201590986A1 (ru) Антитела к ceacam5 и их применения
EA201101516A1 (ru) Антитела, специфические для кадгерина-17
BRPI0808940A8 (pt) anticorpo humano ou fragmento de ligação do mesmo, antígeno, polinucleotídeo, vetor, célula hospedeira, método para preparar um anticorpo ou um fragmento de ligação ou cadeia(s) de imunoglobulina do mesmo, anticorpo, cadeia de imunoglobulina ou um fragmento de ligação do mesmo, composição, usos do anticorpo ou fragmento de ligação, de um antígeno, de um polinucleotídeo, de um vetor, ou de uma célula, e de uma molécula de ligação a antígeno tumoral, método para clonagem molecular de um anticorpo, e, kit para o diagnóstico de um tumor
EA201300470A1 (ru) Антитела
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
MX2011008456A (es) Anticuerpos anti-mst1r y usos de los mismos.
NO20091662L (no) Nye antigener og antistoffer assosiert med pankreatisk, duktalt adenokarsinom